Tejara Capital Ltd Invests $1.11 Million in Teladoc Health, Inc. $TDOC

Tejara Capital Ltd bought a new position in Teladoc Health, Inc. (NYSE:TDOC) during the fourth quarter, Holdings Channel reports. The fund bought 159,200 shares of the health services provider’s stock, valued at approximately $1,114,000.

Several other hedge funds have also modified their holdings of the stock. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its holdings in shares of Teladoc Health by 62.3% during the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 243,525 shares of the health services provider’s stock valued at $1,705,000 after purchasing an additional 93,450 shares during the last quarter. International Assets Investment Management LLC purchased a new position in Teladoc Health in the 4th quarter worth about $45,000. Hussman Strategic Advisors Inc. raised its holdings in Teladoc Health by 42.9% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 210,000 shares of the health services provider’s stock worth $1,470,000 after buying an additional 63,000 shares during the period. Oppenheimer & Co. Inc. raised its holdings in Teladoc Health by 6.6% during the 4th quarter. Oppenheimer & Co. Inc. now owns 140,557 shares of the health services provider’s stock worth $984,000 after buying an additional 8,722 shares during the period. Finally, Jennison Associates LLC lifted its stake in Teladoc Health by 19.0% during the fourth quarter. Jennison Associates LLC now owns 100,360 shares of the health services provider’s stock valued at $703,000 after buying an additional 16,058 shares in the last quarter. 76.82% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TDOC has been the topic of several analyst reports. Wells Fargo & Company dropped their target price on shares of Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, February 26th. Piper Sandler reiterated an “overweight” rating and set a $9.00 price objective (down from $12.00) on shares of Teladoc Health in a research report on Thursday, February 26th. Barclays cut their target price on shares of Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 26th. Oppenheimer reduced their target price on Teladoc Health from $12.00 to $7.00 and set an “outperform” rating for the company in a report on Tuesday, March 3rd. Finally, BMO Capital Markets decreased their target price on Teladoc Health from $8.00 to $5.00 and set a “market perform” rating for the company in a research report on Thursday, February 26th. Five investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Teladoc Health presently has a consensus rating of “Hold” and an average price target of $7.53.

Insider Buying and Selling

In other Teladoc Health news, CEO Charles Divita III sold 27,731 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total value of $152,243.19. Following the transaction, the chief executive officer owned 364,784 shares in the company, valued at $2,002,664.16. The trade was a 7.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.70% of the stock is owned by company insiders.

Teladoc Health Stock Down 2.9%

Teladoc Health stock opened at $6.60 on Friday. Teladoc Health, Inc. has a twelve month low of $4.40 and a twelve month high of $9.77. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.72 and a current ratio of 2.80. The firm has a market cap of $1.19 billion, a PE ratio of -6.80 and a beta of 2.08. The firm’s 50 day moving average price is $5.70 and its two-hundred day moving average price is $6.32.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The company had revenue of $613.85 million for the quarter, compared to analyst estimates of $611.04 million. During the same period last year, the business earned ($0.53) EPS. The company’s quarterly revenue was down 2.5% on a year-over-year basis. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. On average, research analysts predict that Teladoc Health, Inc. will post -0.92 EPS for the current fiscal year.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.